Apparently pretty close.
One paragraph from the article:
"On the day that the UCL trial's success was declared, the Swiss pharmaceutical giant Roche announced that it would take up a $45 million option to move IONIS-HTTRx on to the next stage: a phase III trial involving hundreds of patients over a longer period to assess whether it can reverse symptoms. At this stage, there's only evidence that it combats the cause of Huntington's in humans, not the disease itself—though Ionis and its collaborators have used an ASO to reverse symptoms in mice."
https://qz.com/1230035/how-close-are-we-to-a-cure-for-huntingtons/
One paragraph from the article:
"On the day that the UCL trial's success was declared, the Swiss pharmaceutical giant Roche announced that it would take up a $45 million option to move IONIS-HTTRx on to the next stage: a phase III trial involving hundreds of patients over a longer period to assess whether it can reverse symptoms. At this stage, there's only evidence that it combats the cause of Huntington's in humans, not the disease itself—though Ionis and its collaborators have used an ASO to reverse symptoms in mice."
https://qz.com/1230035/how-close-are-we-to-a-cure-for-huntingtons/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.